MDMA harm (n = 893) | Non-MDMA harm (n = 893) | |||
---|---|---|---|---|
Effect | OR (95% CI) | aOR (95% CI) | OR (95% CI) | aOR (95% CI) |
Age | ||||
18–21 vs. 36+ | 1.87 (0.81–4.29) | 2.38 (0.91–6.22) | 0.98 (0.52–1.83) | |
22–25 vs. 36+ | 2.22 (0.96–5.15)a | 2.49 (0.94–6.58) | 0.94 (0.49–1.80) | |
26–29 vs. 36+ | 1.38 (0.55–3.50) | 1.51 (0.53–4.33) | 0.99 (0.49–1.99) | |
30–35 vs. 36+ | 0.88 (0.88–2.54) | 1.06 (0.32–3.49) | 0.80 (0.37–1.73) | |
Female gender | 1.21 (0.82–1.79) | 1.01 (0.71–1.42) | ||
Māori ethnicity | 0.84 (0.48–1.48) | 1.03 (0.64–1.66) | ||
Student | 1.13 (0.78–1.64) | 0.90 (0.64–1.26) | ||
Region of residence (ref = Otago) | ||||
Auckland | 1.08 (0.61–1.89) | 1.26 (0.76–2.09) | ||
Wellington | 1.13 (0.62–2.07) | 1.48 (0.87–2.51) | ||
Canterbury | 1.11 (0.65–1.88) | 1.27 (0.79–2.06) | ||
Other | 1.23 (0.71–2.16) | 1.37 (0.82–2.28) | ||
Frequency of MDMA use (ref = once a year or less often) | ||||
Weekly or more often | 6.92 (3.1-15.46)*** | 5.05 (1.93–13.24)* | 2.74 (1.01–7.42)* | 1.31 (0.42–4.04) |
Fortnightly | 1.71 (0.73–3.99 | 0.73 (0.25–2.11) | 4.94 (2.15–11.35)*** | 3.25 (1.25–8.44)* |
Monthly | 1.54 (0.76–3.13 | 0.87 (0.38-2.00) | 4.44 (2.13–9.28)*** | 3.17 (1.40–7.15)** |
Every 2–3 months | 1.38 (0.72–2.68) | 0.75 (0.35–1.63) | 3.49 (1.72–7.10)*** | 2.56 (1.17–5.60)* |
Every 4–6 months | 1.22 (0.62–2.42) | 0.84 (0.39–1.82) | 2.46 (1.18–5.14)* | 1.95 (0.88–4.33) |
Average dose per session (ref = 100 mg) | ||||
< 50 mg | 0.33 (0.10–1.06)a | 0.28 (0.08-1.00) | 0.78 (0.26–2.32) | 1.65 (0.52–5.25) |
51-99 mg | 0.84 (0.35–1.99) | 0.84 (0.33–2.16) | 1.28 (0.50–3.28) | 1.60 (0.58–4.42) |
101-150 mg | 0.51 (0.22–1.16) | 0.39 (0.16–0.96)* | 1.57 (0.69–3.58) | 1.65 (0.68–4.01) |
151-250 mg | 0.97 (0.48–1.96) | 0.66 (0.30–1.46) | 2.37 (1.10–5.11)* | 2.15 (0.94–4.94) |
251-500 mg | 0.95 (0.45–2.01) | 0.57 (0.24–1.39) | 3.24 (1.48–7.10)** | 2.89 (1.22–6.87)* |
> 500 mg | 1.79 (0.76–4.21) | 0.68 (0.23–2.04) | 1.36 (0.49–3.79) | 1.19 (0.38–3.78) |
“I don’t know” | 0.80 (0.37–1.72) | 0.81 (0.35–1.89) | 1.30 (0.56–3.01) | 2.16 (0.86–5.39) |
Self-reported harm reduction knowledge (ref = know nothing) | ||||
Know little | 0.91 (0.43–1.91) | 2.01 (0.81–4.50) | 1.97 (0.75–5.18) | |
Know moderate amount | 0.88 (0.43–1.77) | 2.31 (0.96–5.55)a | 1.91 (0.74–4.93) | |
Know large amount | 0.68 (0.32–1.46) | 3.07 (1.25–7.53)* | 2.47 (0.92–6.60) | |
MDMA harm | - | - | 5.57 (3.73–8.32)*** | 6.38 (4.06–10.03)*** |
Non-MDMA harm | 5.57 (3.73–8.32)*** | 6.29 (3.99–9.92)*** | - | - |
Use of KYSNZ | 1.95 (1.32–2.89)*** | 2.50 (1.56–3.99)*** | 1.92 (1.35–2.74)*** | 1.13 (0.74–1.73) |
Use of colorimetric reagent test | 1.28 (0.88–1.86) | 2.15 (1.53–3.03)*** | 1.60 (1.06–2.41)* | |
Meets dependence threshold | 6.34 (3.67–10.97)*** | 5.22 (2.70–3.99)*** | 1.64 (0.90–2.99) | |
Constant | 0.05*** | 0.01*** | ||
Hosmer and Lemeshow Goodness-of-fit | 0.359 | 0.744 |